Program
Folfox protocol
Also written as “sunitinib + FOLFOX”, “FOLFOX” and “FOLFOX regimen”.
Its studies are mostly in Colorectal Neoplasms · Cholangiocarcinoma · Stomach Neoplasms · Neoplasms, led by 11 companies.
Drug pageFolfox protocol: every studyMany companies study it; this page follows only the 15 they lead. All 89 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 31 open or running | phase 1since Feb 23, 2009 | Feb 23, 2009 | Aug 31, 2030phase 1 · NCT04929223 |
| AstraZeneca | 21 open or running | phase 3since Nov 13, 2006 | Nov 13, 2006 | Nov 30, 2027phase 2 · NCT05702229 |
| Pfizerits history only | 20 open or running | phase 2since Feb 1, 2008 | Jan 11, 2008 | none ahead |
| Alethia Biotherapeuticsits history only | 11 open or running | phase 2since Nov 17, 2023 | Nov 17, 2023 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Mar 20, 2009 | Mar 20, 2009 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since May 24, 2007 | May 24, 2007 | none ahead |
| Cardiff Oncologyits history only | 11 open or running | phase 2since Oct 24, 2023 | Oct 24, 2023 | Apr 16, 2027phase 2 · NCT06106308 |
| Fosun Pharmaits history only | 11 open or running | phase 2since Apr 2, 2025 | Apr 2, 2025 | Apr 30, 2028phase 2 · NCT06936527 |
| Genmabits history only | 11 open or running | phase 2since Apr 4, 2018 | Apr 4, 2018 | May 2028phase 2 · NCT03526835 |
| Lisata Therapeuticsits history only | 10 open or running | phase 2since Jan 26, 2023 | Jan 26, 2023 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 2since Oct 22, 2008 | Oct 22, 2008 | none ahead |
Also a collaborator on its studies: Merck Pte. Ltd., Singapore.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2006First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT00399035 · 1,254 enrolled · Argentina, Australia, Brazil and more
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsNCT05702229 · 163 planned · United States, China, Japan and more
Ahead
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | Nov 30, 2027 | 163 |
| NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more | 3 | Completed | Mar 2010 | 1,254 |
How it is read
Names in the registry
- “sunitinib + FOLFOX”, 7 entries
- “FOLFOX”, 6 entries
- “FOLFOX regimen”, 2 entries
- “FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])”, 2 entries
- “MCLA-158 + FOLFOX”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 12 studies
- Cholangiocarcinoma, 1 study
- Stomach Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.